MedWatch

Ambu's stock hits lowest price in five years

An analyst from Carnegie says there are several factors explaining why the medtech firm’s share price has declined to a level not seen since 2017.

Photo: PR / Ambu

Ambu has been facing headwinds on the stock exchange in recent days, and Head of Equity Research at Carnegie Investment Bank Niels Granholm-Leth has identified several potential factors as to why.

”It seems as if there might have been some exaggerated fears that the company might have to bring in new capital to continue its current strategy. It’s far from certain that the company’s new leadership will continue the previous capital-demanding course,” assesses Granholm-Leth says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs